Options
Can histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophies
Date Issued
2017-12-13
Date Available
2019-05-08T14:06:55Z
Abstract
Inherited retinal dystrophies (iRDs) affect 1 in 3000 people worldwide and effective treatment options are not widely available due to the genetic and clinical heterogeneity. Recently, histone deacetylase inhibitors (HDACi) have gained attention as a potential therapeutic option based on their neuroprotective effects within the retina. However, the benefits of HDACi remains highly controversial, and their downstream mechanism of action are yet to be thoroughly elucidated. Preliminary data from studies conducted has shown that treatment of zebrafish retinal mutant with HDACi, trichostatin A (TSA), could rescue visual capacity and retinal morphology. The current study is designed to address the suitability of HDACi as therapeutic options for iRDs using zebrafish models.
Other Sponsorship
Fighting Blindness
Type of Material
Conference Publication
Language
English
Status of Item
Peer reviewed
Conference Details
British Pharmacological Society (BPS) Pharmacology 2017, London, England, 11-13 December 2017
ISSN
1741-1157
This item is made available under a Creative Commons License
File(s)
Loading...
Name
1vol18issue1abst172p.pdf
Size
54.15 KB
Format
Adobe PDF
Checksum (MD5)
5727ff15d1aef075d64058cec94564ed
Owning collection